REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Data ReadoutpositiveSurabgene LomparvovecPositive

AI Analysis

Summary

REGENXBIO presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy, demonstrating sustained vision improvement in the majority of treated patients with no vision-threatening events. The data was presented at the Retina Society Annual Scientific Meeting.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Three-year durability data showed majority of Dose Level 3 participants with NPDR demonstrated >2-step DRSS improvement at 3 years post-treatment, with no vision-threatening events and no additional treatment needed

Importance:7/10

Sentiment:

0.85

gene therapydiabetic retinopathydurability datathree-year resultsNPDRophthalmology

Related Companies

$RGNX

Read the original article

Published by PR Newswire Pharma on September 24, 2026 11:17 PM

Read Original